Can stem cells fix spina bifida before birth?

Early clinical steps show safety and functional promise

A small, first-in-human trial treating spina bifida in utero with a stem-cell patch has delivered encouraging early results. Surgeons applied a patch made from placenta-derived stem cells during the standard fetal repair procedure; the intent was to protect exposed neural tissue and promote better neurological development before birth. Patients in the study experienced improved short-term outcomes compared with historic expectations, and investigators reported the procedure was safe in the treated pregnancies.

What changed for infants

• The stem-cell patch offers a biological dressing over the spinal lesion that may reduce ongoing damage to exposed nerves in the womb.
• Early measures showed improvements in key health indicators and in quality-of-life outcomes for babies and families, suggesting the treatment can augment the benefits of surgical repair.
• No serious safety concerns attributable to the cells emerged in the initial small cohort, a crucial step before larger trials.

What remains uncertain

Long-term effectiveness is still unknown. The initial trial was small and focused on safety and short-term function; researchers must follow treated children as they grow to see whether the early gains persist in mobility, bladder and bowel control, and other developmental outcomes. Larger, controlled trials are already being planned or underway to test whether the cellular patch consistently improves neurological development and to monitor for rare risks over years.

If larger studies confirm the early promise, adding regenerative biology to fetal surgery could become a major shift in how congenital neural defects are treated—reducing lifelong disability by intervening while the nervous system is still forming.